•
git+ is a lifestyle
Talks about Git, Github and git workflow
JR
Jason Rhodes
Chairman (and founding CEO) at Generation Bio
Cambridge, Massachusetts
Overview
Jason Rhodes is a Partner at Atlas Venture in Cambridge, Massachusetts, with a focus on venture capital investments in the life sciences and biotechnology sectors. Notable highlights of his career include serving as founding CEO and Chairman of multiple successful startups like Rectify Pharma and Generation Bio, and leading investments in companies like Accent Therapeutics and Disarm Therapeutics.
Rhodes has an impressive track record of leadership roles in the pharmaceutical industry, including being the President and CFO at Epizyme and Vice President of Business Development at Alnylam. His extensive experience in founding and chairing successful companies, coupled with his strategic investments in groundbreaking startups, showcases his expertise in driving innovation and growth in the life sciences sector.
Work Experience
Partner
2014 - Current
Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Executive Chair (and founding CEO)
2020
Rectify Pharmaceuticals is a biotechnology company developing Positive Functional Modulators (PFMs), disease-modifying therapeutics.
Raised $100,000,000.00 from Forbion Capital Partners, Longwood Fund, Omega Funds and Atlas Venture.
Chairman (and founding CEO)
2016
www.generationbio.com
Generation Bio is a biotechnology company that develops genetic medicines to treat genetic disorders.
Raised $536,400,000.00 from Moderna.
Chairman (and founding CEO)
2017
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Raised $940,100,000.00 from Logos Capital, Wellington Management, Vida Ventures, Franklin Templeton, Surveyor Capital, Forbion Capital Partners, Atlas Venture and MPM Capital.
Presidential Advisory Council, Member
2009 - 2022
Chairman (and founding CEO)
2016 - 2020
President and CFO
2010 - 2014
Vice President, Business Development
2007 - 2010
Alnylam is a biopharmaceutical company developing novel therapeutics based on RNAi. Led strategic collaborations with Takeda, GSK, Kyowa Hakko Kirin, Medtronic, Cubist and Roche, and spin out of Regulus (RGLS).
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Raised $3,884,600,000.00 from Blackstone Life Sciences, Regeneron, Genzyme and Takeda.
Partner
2001 - 2007
Biotech venture capital arm of Fidelity Investments. Led investments in therapeutics companies including FoldRx, acquired by Pfizer.